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Animal thioredoxin reductases (TRs) are selenocys-
teine-containing flavoenzymes that utilize NADPH for
reduction of thioredoxins and other protein and non-
protein substrates. Three types of mammalian TRs are
known, with TR1 being a cytosolic enzyme, and TR3, a
mitochondrial enzyme. Previously characterized TR1
and TR3 occurred as homodimers of 55–57-kDa subunits.
We report here that TR1 isolated from mouse liver,
mouse liver tumor, and a human T-cell line exhibited
extensive heterogeneity as detected by electrophoretic,
immunoblot, and mass spectrometry analyses. In partic-
ular, a 67-kDa band of TR1 was detected. Furthermore, a
novel form of mouse TR1 cDNA encoding a 67-kDa sel-
enoprotein subunit with an additional N-terminal se-
quence was identified. Subsequent homology analyses
revealed three distinct isoforms of mouse and rat TR1
mRNA. These forms differed in 5* sequences that re-
sulted from the alternative use of the first three exons
but had common downstream sequences. Similarly, ex-
pression of multiple mRNA forms was observed for hu-
man TR3 and Drosophila TR. In these genes, alternative
first exon splicing resulted in the formation of predicted
mitochondrial and cytosolic proteins. In addition, a hu-
man TR3 gene overlapped with the gene for catechol-O-
methyltransferase (COMT) on a complementary DNA
strand, such that mitochondrial TR3 and membrane-
bound COMT mRNAs had common first exon sequences;
however, transcription start sites for predicted cytoso-
lic TR3 and soluble COMT forms were separated by ;30
kilobases. Thus, this study demonstrates a remarkable
heterogeneity within TRs, which, at least in part, results
from evolutionary conserved genetic mechanisms em-
ploying alternative first exon splicing. Multiple tran-
scription start sites within TR genes may be relevant to
complex regulation of expression and/or organelle- and
cell type-specific location of animal thioredoxin
reductases.
The thioredoxin redox system is one of two major redox
systems in animal cells, which, together with the glutathione
system, participates in the redox control of a great variety of
biological processes involved in cell life and death (1–3). Dis-
ruption of the gene for thioredoxin 1, a 12-kDa thiol disulfide
oxidoreductase, results in embryonic lethality in mice (4) dem-
onstrating an essential role of the thioredoxin system in the
development of mammals. Three distinct thioredoxin reduc-
tases (TRs)1 (5–10) are responsible for maintaining thioredox-
ins in a reduced state and are also capable of reducing a great
variety of other protein and nonprotein redox substrates. The
cytosolic thioredoxin reductase (TR1), the most characterized of
the three enzymes, was known for decades, but only recently it
was found to be a selenium-containing protein (11). TR1 con-
tains a C-terminal penultimate selenocysteine residue encoded
by TGA (12), and this residue is essential for catalytic activity
of the enzyme (13–15).
One of the first indications that multiple TR forms occur in
mammalian cells was immunoblot analyses of various human
TR preparations. An enzyme possessing TR activity that was
isolated from a human lung adenocarcinoma cell line NCI-
H441 failed to react with antibodies specific for rat liver TR1
(11), whereas TR isolated from a human T-cell line JPX9 re-
acted with these antibodies (12). Determination of internal
peptide sequences of the T-cell TR demonstrated that this
protein was TR1 (12). Unfortunately, the NCI-H441 enzyme
was not sequenced, and in retrospect it seems possible, that
this TR could have been encoded by a different gene. In addi-
tion to a TR form not reacting with anti-TR1 antibodies, sub-
sequent studies identified two forms of TR1 isolated from ei-
ther NCI-H441 or HeLa cells that showed a positive
immunoblot signal with these antibodies (16–18). Yet, these
forms differed in catalytic activity, selenium content, and af-
finity for column matrices. In particular, forms that differed in
the ability to bind to a heparin column were extensively char-
acterized (16–18). However, differences in either protein or
gene sequences, or in post-translational modifications that
were responsible for the observed changes in catalytic and
chromatographic properties, were not reported.
Recently, two additional thioredoxin reductases, TR2 and
TR3, were identified that contained the conserved selenocys-
teine residue (5–10). These enzymes had also other sequences
essential for catalytic activity, including an N-terminal disul-
fide active center, NADPH- and FAD-binding domains and
dimer interface sequences (5–10). The three TR enzymes
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showed .50% sequence identity, although TR1 and TR2 were
closely related enzymes, while TR3 was a more evolutionary
distant enzyme (10). TR3 (also called TRb (5) and TrxR2 (6)),
like TR1, appeared to be ubiquitously expressed (5–10). This
enzyme was described as a mitochondrial thioredoxin reduc-
tase because it was shown to contain a mitochondrial signal
peptide. In addition, this protein was localized in mitochondria
by detecting various transiently expressed, tagged forms of
TR3 and by immunoblot assays with antibodies specific for TR3
(5–10). TR2 had not been extensively characterized nor its full
amino acid sequence reported (10).
In the present report, we describe the occurrence of multiple
forms of TR1 and TR3 and utilize genetic and biochemical
techniques to characterize the basis for heterogeneity within
animal TR preparations. We find differences in 59-end cDNA
sequences for mammalian TR1, mammalian TR3, and Dro-
sophila TR that resulted from the alternative use of first exons.
EXPERIMENTAL PROCEDURES
Partial Isolation of Mouse TRs from Normal Livers and Liver Tumors
on an ADP-Sepharose Column—Male wild type and transforming
growth factor a (TGFa)/c-myc double transgenic mice (6–15 months old)
were maintained and labeled with 75Se, and their livers and liver
tumors were dissected as described previously (19). The coexpression of
TGFa and c-Myc results in multiple liver tumor formation by 6 months
of age. Three unlabeled wild type mouse livers (4 g) and a single
75Se-labeled wild type liver (0.5 g) were mixed and homogenized in 10
ml of 40 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.6 mM
4-(2-aminoethyl)benzenesulfonyl fluoride, 5 mg/ml aprotinin, and 5
mg/ml leupeptin (buffer A). The homogenate was centrifuged at 18,000
rpm for 20 min, and the supernatant was loaded directly onto a 3-ml
ADP-Sepharose (Amersham Pharmacia Biotech) column. The column
was washed extensively with 150 mM NaCl and 40 mM Tris-HCl, pH 7.5,
and proteins were eluted with 1 M NaCl in 40 mM Tris-HCl, pH 7.5.
Protein fractions were tested by SDS-PAGE and immunoblot analyses
with antibodies specific for TR1 and TR3 (10), pooled, and further
analyzed by a two-dimensional gel electrophoresis. TR1 was also iso-
lated from TGFa/c-myc tumors using the same procedure except that 5
unlabeled liver tumors (11.5 g) and one 75Se-labeled liver tumor (3.5 g)
were homogenized in 15 ml of buffer A.
TR1 Purification—TR1 was isolated from mouse liver, rat prostate,
and a human T-cell line JPX9 according to a three-step procedure that
involved DEAE-Sepharose (Amersham Pharmacia Biotech), ADP-
Sepharose, and phenyl-HPLC columns (TosoHaas) as described previ-
ously (12). To obtain 75Se-labeled TR1, unlabeled mouse livers were
mixed with a single 75Se-labeled wild type liver. Isolated proteins were
analyzed by immunoblot assays with antibodies specific for TR1, TR2,
and TR3 (10), protein staining with Coomassie Blue and by detecting
75Se with a PhosphorImager (Molecular Dynamics). To further fraction-
ate the enzyme, TR1 preparation was dialyzed against 20 mM Tris-HCl,
pH 7.0, and applied onto a heparin-HPLC column (TosoHaas). The
proteins were eluted with a gradient of 20–500 mM Tris-HCl, pH 7.0.
75Se was detected in fractions with a g-counter. JPX9 cells were grown
on an RPMI 1640 medium in the presence of 10% fetal bovine serum
and metabolically labeled with 75Se as described previously (12). Hu-
man A431 cell line was grown as described (10) and TRs were purified
from sonicated crude extracts on an ADP-Sepharose column as de-
scribed for mouse enzymes.
Two-dimensional Gel Electrophoresis—Two-dimensional gel electro-
phoresis of 75Se-contining polypeptides was performed as described
previously (20). Briefly, 25 ml of each TR preparation (500 mg of total
protein), which was partially purified on an ADP-Sepharose column,
were resolved in the first dimension on an isoelectric focusing (IEF) gel,
followed by separation in the second dimension on a 10% polyacryl-
amide gel under reducing conditions. The separated polypeptides were
electroblotted on polyvinylidene difluoride membranes, the blots
stained with Ponceau S, and the 75Se-containing proteins detected on
the dried membranes by the PhosphorImager analysis.
Peptide Mapping—TR samples purified by one-dimensional or two-
dimensional gel electrophoresis were transferred onto polyvinylidene
difluoride membranes and stained with either Ponceau S or Sulforo-
damine B. Bands were excised and digested with trypsin as described
(21). After digestion, peptides were extracted from the membrane with
the addition of 10 ml of formic acid:ethanol (1:1) for 1 h at room tem-
perature. 0.5 ml were sampled directly from the supernatant to the
matrix-assisted laser desorption ionization (MALDI) plate, mixed
with 0.5 ml of a-cyano-4-hydroxy cinnamic acid matrix (10 mg/ml in
acetonitrile/trifluoroacetic acid, 0.1%) and allowed to air-dry before
data collection. Spectra were acquired on a Voyager RP mass spec-
trometer using oxidized bovine insulin b chain as internal standard
for calibration (21, 22).
Mass Spectrometric Analysis of Intact Human TR Molecules—Mass
spectrometric analysis of native or alkylated human TR proteins was
performed on a API300 triple quadrupole mass spectrometer equipped
with a Micro-IonSpray source. Prior to MS analysis proteins were
purified by RP-HPLC on a narrow-bore Vydac C4 column (150 3 2.1
mm, 5 mm) using a linear gradient of 0–70% acetonitrile containing
0.1% trifluoroacetic acid and a flow rate of 250 ml/min. Samples were
manually collected and directly injected into the mass spectrometer ion
source by infusion at 1 ml/min. Reduction and alkylation of TRs was
conducted in denaturing conditions (6 M guanidine HCl, pH 8.0) using
iodoacetamide as an alkylating agent.
Other Procedures—Mouse cDNA clones (clone ID 607552, accession
number AI662374, Stratagene mouse skin cDNA library; and clone ID
2064717, accession number AI789478, Sugano mouse kidney-mkia
cDNA library) were purchased from Research Genetics and their insert
sequences experimentally determined. The two clones overlapped for
510 nucleotides and the combined cDNA sequence was 3626 nucleotides
long. SDS-PAGE, immunoblot, and isoelectrofocusing analyses were
performed with electrophoretic supplies and gels from Novex. Immuno-
blot membranes were developed with a SuperSignal detection kit
(Pierce) or an ECL detection kit (Amersham Pharmacia Biotech) using
previously developed antibodies specific for TR1, TR2, and TR3 (10). We
have previously demonstrated strict isozyme specificity of these anti-
bodies (10). Nucleotide sequences were analyzed with BLAST programs
(23). Exons were predicted with a NetGene2 program. Mitochondrial
signal peptides were predicted with the PSORT II or SignalP programs.
RESULTS
Heterogeneity within Mouse Thioredoxin Reductase Prepara-
tions—To determine whether mouse TR1 occurs in multiple
forms and if the distribution of these forms differs between
normal and malignant cells, we partially isolated TRs from a
pool of 75Se-labeled wild type mouse livers and from a pool of
75Se-labeled liver tumors developed in TGFa/c-myc double
transgenic mice. To minimize potential losses of certain TR
forms due to different elution profiles of these forms on col-
umns commonly used in TR isolation procedures, we utilized
only a single step, an affinity ADP-Sepharose chromatography,
to purify TRs.
When 75Se-labeled protein extracts obtained from either nor-
mal livers or liver tumors were fractionated on an ADP-Sepha-
rose column, TR1, seen as a 75Se-labeled band (Fig. 1A, lanes 3
and 6), and TR3, which is masked by TR1 due to its lower
abundance (6, 10), were separated from the remainder of 75Se-
labeled proteins (Fig. 1A). Two other major 75Se-labeled pro-
teins that did not bind to the column were glutathione peroxi-
dase 1 (GPx1) and glutathione peroxidase 4 (GPx4) (19). Since
we used identical procedures for fractionation of normal and
tumor samples, comparison of GPx1 and other selenoprotein
bands in normal (Fig. 1A, lane 1) and tumor (Fig. 1A, lane 4)
samples suggested that the levels of GPx1 were decreased in
tumors. A similar decrease was previously observed when nor-
mal livers from TGFa/c-myc mice were compared with liver
tumors from the same mice (19). On the other hand, the latter
studies found that expression of TR1 was slightly increased in
liver tumors relative to surrounding normal livers in TGFa/c-
myc mice (19). Fig. 1B shows immunoblot analyses of mouse
TR1 and TR3 enriched from normal wild type and transgenic
malignant livers on an ADP-Sepharose column. Proteins iso-
lated from these two sources migrated similarly on SDS-PAGE.
TR1 had a molecular mass of ;57 kDa, whereas TR3 migrated
as an ;55-kDa protein. Although TR1 is more abundant than
TR3 in liver (16), the ratio of these enzymes was approximately
the same in wild type and tumor samples (Fig. 2B), suggesting
that expression of TR3, like that of TR1 (but in contrast to
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GPx1), was unchanged or perhaps somewhat elevated during
malignant transformation in TGFa/c-myc mice.
In addition to the mouse samples, we analyzed TR1 isolated
from rat prostate by a standard three-column procedure (Fig.
1B, lane 3), and a TR preparation isolated from a human
epidermoid A431 cell line using a single ADP-Sepharose col-
umn (Fig. 1B, lane 4). Interestingly, although the major form of
human TR1 migrated as a 57-kDa band, human TR3 was
present as a mixture of 55–57-kDa species.
While mouse TR preparations isolated from normal and tu-
mor samples migrated as single species and exhibited similar
electrophoretic properties on SDS-PAGE gels (Fig. 1B), this
electrophoretic technique is often insufficient to resolve minor
differences within preparations. Therefore, to further test pro-
tein preparations shown in Fig. 1B, lanes 1 and 2, we sepa-
rately analyzed normal and tumor TRs by two-dimensional gel
electrophoresis. Comparison of 75Se and protein profiles on
two-dimensional gels for normal and tumor samples suggested
that all signals shown in Fig. 2 corresponded to TR1. TR3 was
not detected on two-dimensional gels because it was present in
lower levels than TR1 and exhibited a different isoelectric
point.
The two-dimensional gel electrophoresis analysis (Fig. 2)
revealed dramatic heterogeneity within TR1 preparations from
normal and tumor samples. TR1 bands were separated on
two-dimensional gels according to both charge and mass. Nine
representative bands from two-dimensional gels for normal
and tumor samples (Fig. 2, E and F) were digested with tryp-
sin. Tryptic digests were analyzed by MALDI time-of-flight
mass-spectrometry (MALDI-TOF MS). Experimentally deter-
mined peptide masses matched to the peptide masses predicted
from the tryptic digestion of a deduced mouse TR1 sequence
(see details of mouse TR1 sequences below) and covered .50%
of the protein sequence (cysteine-containing and N-terminal
peptides were not detected). No post-translational modifica-
tions within TR1 that could potentially contribute to different
mobilities of TR1 forms on two-dimensional gels were detected.
In addition, no significant differences in tryptic peptide maps
were found between normal and tumor samples.
In addition to multiple TR1 forms that were resolved by
two-dimensional gel electrophoresis (Fig. 2) but migrated as a
single 57-kDa band on SDS-PAGE gels (Fig. 1B), we detected
TR1 forms that significantly differed from the 57-kDa isoforms.
We noted that longer exposure of 75Se signals detected with a
PhosphorImager and analysis of anti-TR1 immunoblot signals
often produced two additional bands, ;67 and ;110 kDa.
These bands partially co-purified with the 57-kDa forms and
FIG. 1. Isolation and characterization of mouse liver thiore-
doxin reductases. A, detection of 75Se by PhosphorImager analysis in
fractions from an ADP-Sepharose column. 75Se-Labeled homogenates
from wild type livers (lanes 1–3) and hepatocarcinomas of TGFa/c-myc
transgenic mice (lanes 4–6) were fractionated on an ADP-Sepharose
column. Flow-through (lanes 1 and 4), low-salt wash (lanes 2 and 5), and
high-salt elution (fractions 3 and 6) fractions were analyzed by SDS-
PAGE analysis. The positions of TR (mixture of TR1 and TR3), GPx1
and GPx4 are indicated on the right. B, immunoblot analyses of mam-
malian thioredoxin reductases. Wild type liver TR fractions (A, lane 3)
and liver tumor TR fractions (A, lane 6) were probed with antibodies
specific for TR1 (upper panel). The blot was then stripped and reprobed
with antibodies specific for TR3 (lower panel). Also analyzed were a
homogenous preparation of a rat prostate TR1 obtained by a three-step
procedure, employing DEAE-Sepharose, ADP-Sepharose, and phenyl-
HPLC columns (shown as Rat prostate, lane 3) and a human TR
preparation obtained by affinity chromatography of a homogenate from
A431 cells on an ADP-Sepharose column (shown as Human A431 cells,
lane 4). The rat sample did not contain TR3, which had different elution
profiles than TR1 from DEAE-Sepharose and phenyl-HPLC columns.
The positions of the 57-kDa form of TR1 and the 55-kDa form of TR3 are
indicated on the right.
FIG. 2. Two-dimensional gel electrophoresis of mouse TR
preparations. Wild type liver and TGFa/c-myc liver tumor TR prepa-
rations were subjected to two-dimensional gel electrophoresis analysis,
followed by detection of 75Se by PhosphorImager analysis (A-D) and
staining of proteins with Ponceau S (E and F). Panels A and B show full
two-dimensional gels, whereas panels C-F show enlarged areas that
correspond to 75Se signals on panels A and B. Panels A, C, and E show
TR1 isolated from wild type livers, and panels B, D, and F, from liver
tumors.
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were present as minor forms in apparently homogeneous en-
zyme preparations. The 67- and 110-kDa species did not cross-
react with anti-TR2 and anti-TR3 antibodies. Migration prop-
erties of the 110-kDa minor band corresponded to that of the
TR1 homodimer, although the biochemical basis for the possi-
ble dimer formation under these conditions is not clear. The
possible origin of the 67-kDa band is discussed below.
Heterogeneity within Human Thioredoxin Reductase Prepa-
rations—We further tested if the extensive heterogeneity ob-
served within mouse TR1 preparations, occurs in human TR1
preparations. For this purpose, we selected a human T-cell line,
JPX9, that was previously used as a source of TR1 (12). To
purify human TR1, we initially utilized a previously developed
three-step procedure (12). The purified protein was analyzed by
electrospray ionization (ESI) mass spectrometry. The recorded
ESI-MS spectra showed a broad peak centered at 54,860 Da,
that was 230 Da more than the mass predicted from the pre-
viously reported human TR1 sequence (24). Reduction and
carboxymethylation of the enzyme increased its mass to 55,626
Da, but did not significantly narrow the mass peak. The differ-
ence between native and carboxymethylated forms, 762 Da,
corresponded to 13.4 alkylated groups. The predicted human
TR1 sequence contained 13 cysteines and 1 selenocysteine.
Considering that isolated TR1 is often contaminated with a
truncated form lacking the last two residues, Sec498 and Gly499,
the data suggested that the isolated TR1 could be fully alky-
lated with iodoacetic acid and that cysteines and selenocysteine
were not modified in the native enzyme.
We further took advantage of a recent observation that hu-
man TR1 could be additionally fractionated on a heparin col-
umn (16–18). Indeed, two peaks for TR1 were eluted from the
column, which were detected as 280-nm absorbing peaks (Fig.
3). The two peaks could also be detected due the absorbance of
a flavin at 450 nm and due to the presence of 75Se in the
fractions. Integration of two major TR1 peaks indicated that
the second-eluted peak (peak II) had 3.8 times higher selenium
content (calculated on the basis of 75Se radioactivity) per mg of
protein compared with the first-eluted peak (peak I). The pos-
sible reduced selenium content of TR1 in peak I is similar to the
previous finding of a HeLa cell TR1 form that had ;0.5 sele-
nium per protein subunit (17). The previously isolated mixture
of human T-cell TR1 forms had ;0.74 selenium per protein
subunit (12), suggesting that it could be a mixture of TR1
molecules with variable selenium content. Lower levels of se-
lenium may be due to a loss of selenium from TR1 due to
hydrolysis in the presence of oxygen or reactive oxygen species,
or due to the presence of a truncated form of TR1 lacking
C-terminal selenocysteine and glycine residues.
The fractions corresponding to Peak I shown in Fig. 3 were
pooled, as were fractions corresponding to Peak II, and the two
samples were further analyzed by SDS-PAGE, immunoblot
assays, and isoelectric focusing (Fig. 4). Major protein forms in
each pool migrated as a 55- and 57-kDa pair of protein bands
with approximately similar staining intensity (Fig. 4A, left
panel). These forms were also detected by immunoblot and
PhosphorImager assays (Fig. 4A, middle and right panels).
This observation was in agreement with a previous finding of
two closely migrating TR1 forms isolated from human JPX9
cells (12). In addition, the pair of 55- and 57-kDa bands was
resolved on gels either run in a nonreducing buffer, or following
reduction with dithiothreitol and alkylation with iodoacetic
acid, or following denaturation in 6 M guanidine HCl, reduction
with dithiothreitol and subsequent carboxymethylation (data
not shown).
The 55- and 57-kDa bands were transferred onto a polyvi-
nylidene difluoride membrane, digested with trypsin, and
masses of tryptic peptides were determined with a MALDI-
time of flight MS. Both bands in the doublet produced essen-
tially identical peptide maps and matched with a set of the
predicted TR1 tryptic peptides. Even in this instance, we could
not detect any Cys-containing peptide, along with the N-termi-
nal and C-terminal peptide. In addition to the 55/57-kDa pair of
bands in peaks I and II, a protein form migrating as a 110-kDa
band was observed in both TR1 samples (Fig. 4A). Like the
mouse 110-kDa band, this form corresponded in size to a pos-
sible TR1 dimer.
Peaks I and II differed in that a minor ;67-kDa species were
present in peak I, but absent in peak II (Fig. 4A). This TR1 form
was detected as a Coomassie Blue-stained band and as a 75Se-
labeled band. It was also reactive in immunoblot assays with
anti-TR1 antibodies. Thus, the minor 67-kDa form of TR1 was
detected in both mouse and human preparations. In addition,
several other minor forms of TR1 were present in peak I of
human TR1. Bands with masses higher than 110 kDa could
potentially be formed by a dimer formation involving the 67-
kDa form.
The protein mixtures present in peaks I and II were further
analyzed by tryptic digests followed by determination of pep-
tide masses by MALDI MS. By matching experimentally ob-
served peptide masses with those predicted from an in silico
tryptic digest of the previously reported human TR1 sequence,
we were able to cover over 70% of the human TR1 sequence.
Again, no peptide masses were detected that matched Cys-
FIG. 3. Fractionation of human TR1 preparations on a heparin
column. TR1 was first isolated from 75Se-labeled human JPX9 cells
using a three-step procedure (12). The enzyme was then further frac-
tionated on a heparin-HPLC column. Proteins eluted were detected by
absorbance at 450 (due to the presence of flavin and shown as the
smaller signal on the upper panel) and 280 nm (shown as the larger
signal on the upper panel) and by detection of 75Se in fractions from the
column using a g-counter (lower panel). For subsequent analyses, frac-
tions corresponding to peak I were pooled, as were those corresponding
to peak II, and further analyzed.
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containing, N-terminal and C-terminal peptides. Spectra ob-
tained from peak I and peak II were virtually identical. The
only differences detected were an ion signal at 2110 Da present
only in peak I and signals at 1446 and 1430 Da present only in
peak II. These peptides could not be assigned in the human
TR1 sequence.
Despite the close similarity observed by SDS-PAGE and
mass spectrometry analyses between the various TR1 forms
present in peaks I and II (Fig. 4A), these proteins had different
migration properties when analyzed by isoelectric focusing
(Fig. 4B). Each form was represented by several protein bands
(Fig. 4B). Overall, the data indicated the presence of multiple
forms of human TR1 that differed in molecular masses and
isoelectric points.
Alternative First Exon Splicing Results in the Formation of
Three Distinct mRNA Isoforms of Mouse and Rat TR1—Having
determined no post-translational modifications, we tested
whether observed heterogeneity within human and mouse TR1
preparations could be explained by genetic variations within
TR1 sequences. In particular, the occurrence of the 67-kDa
form of TR1, which was ;10 kDa larger than the protein
deduced from known mammalian TR1 cDNAs, could not be
easily explained without invoking genetic mechanisms. During
the time of our analysis, no mouse TR1 sequences were avail-
able in GenBankTM. Therefore, we obtained a cDNA sequence
of mouse TR1 by sequencing multiple EST clones. Surprisingly,
the final 3626-nucleotide cDNA sequence encoded a protein of
613 residues that had a predicted mass of 67.1 kDa. The de-
duced polypeptide contained the C-terminal penultimate sel-
enocysteine residue encoded by a TGA codon and all sequence
features found in other animal TR sequences (N-terminal di-
sulfide active center, NADPH- and FAD-binding domains and a
dimer-interface domain). The predicted protein differed from
the previously reported 499-amino acid sequences for mamma-
lian TR1s (24, 25) in that the mouse protein had 114 additional
N-terminal residues. The new N-terminal sequence had no
homology to coding regions of other proteins when analyzed
using BLAST programs against nonredundant (NR) and EST
data bases, except that it exhibited .70% identity with se-
quences deduced from a rat genomic clone that contained a
partial sequence of the TR1 gene (accession number
AF189711).
A second mouse TR1 sequence, which encoded a 499-amino
acid protein, has recently appeared in GenBankTM (accession
number AB027565). Comparison of two mouse TR1 cDNA se-
quences revealed identity in .3 kilobases that spanned most of
the coding region and the entire 39-untranslated region. These
sequences, however, had no homology in 59-end sequences (Fig.
5). Subsequent BLAST analyses of mouse dbEST revealed a
mouse EST sequence (accession number AI956288) correspond-
ing to a third TR1 form that had an additional distinct version
of the 59-end sequence, but was identical with the two full-size
cDNA sequences in the downstream region (Fig. 5). The use of
three independent 59 variants deviating from each other at the
same place within the nucleotide sequence was reminiscent of
the alternative use of three exons; that is, different 59 se-
quences corresponded to alternative first exons, while common
sequences corresponded to common downstream exons.
This proposition was consistent with the BLAST analysis of
rat NR and EST data bases using sequences for three forms of
mouse TR1 mRNA. It revealed three potential forms of rat TR1
mRNA that corresponded to the three mouse mRNA forms (Fig.
5). Moreover, the availability of the partial sequence for the rat
TR1 gene allowed us to predict partial features of an exon-
intron structure within this region (Fig. 6). The first exon
within the rat genomic sequence corresponded to the 59 end of
our mouse TR1 cDNA sequence, whereas the second exon that
was separated from the first exon by an ;1.5-kilobase long
FIG. 4. Characterization of human TR1 preparations by gel
electrophoresis. A, SDS-PAGE analyses. Two TR1 preparations
(peaks I and II; see Fig. 3) were subjected to SDS-PAGE analyses
followed by detection of proteins by Coomassie Blue staining (left pan-
el), immunoblot analyses with antibodies specific for TR1 (middle pan-
el), and detection of 75Se by PhosphorImager analyses (right panel). For
better visualization of protein, immunoblot and 75Se signals, three
times more material was loaded on the gel from peak I than from peak
II. The positions of the 55- and 110-kDa forms are indicated on the left.
B, isoelectric focusing. Two TR1 preparations (peaks I and II) were
subjected to isoelectric focusing followed by detection of proteins by
Coomassie Blue staining (left panel) or detection of 75Se by Phosphor-
Imager analyses (right panel). The positions and apparent isoelectric
points of three standards are shown on the left.
FIG. 5. Nucleotide sequence comparisons of TR1 forms ob-
tained by alternative first exon splicing in mice and rats. Each of
the three forms was represented by mouse and rat sequences. The three
forms had distinct 59 sequences (exons 1, 2, or 3), but shared down-
stream sequences (exon 4). Shown in this figure are: MTR1-I, first form
of mouse TR1 (accession number AB027565, dbNR cDNA sequence);
MTR1-II, second form of mouse TR1 (accession number AI956288,
dbEST sequence); MTR1-III, third form of mouse TR1 (this work);
RTR1-I, first form of rat TR1 (accession number AF220761, dbNR
cDNA sequence); RTR1-II, second form of rat TR1 (accession number
AF108213, dbNR cDNA sequence); RTR1-III, third form of rat TR1
(accession number AF189711, dbNR genomic sequence); and RTR1
gene, partial sequence of the rat TR1 gene (accession number
AF189711, dbNR genomic sequence). ATG codons that correspond to
the previously predicted initiation site within mammalian TR1 se-
quences are shown in uppercase. Intronic sequence is boxed. The verti-
cal line indicates sites for junction of exons 1, 2, or 3 to exon 4. Numbers
on the left correspond to nucleotide numbers for GenBankTM sequences
shown in the figure.
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intron, corresponded to the first common exon within the three
forms.
The three TR1 forms, TR1-I, TR1-II, and TRI-III (Fig. 6),
were designated according to order of exons within genomic
sequences, which was derived from the following observations.
The first exon of the TR1-III sequence was present in the rat
genomic clone that also contained the downstream sequences
common for three TR1 forms, whereas the first exons of the
TR1-I and TR1-II sequences were not present in the rat
genomic clone sequence. Thus, 59 exons of TR1-I and TR1-II
were upstream of the 59 exon of TR1-III. We also found several
EST sequences (accession numbers AI526517, AI527732,
AI226627, AI787452, AI314145, and AI315024) that contained
partial sequences for first exons of TR1-I and TR1-II as well as
downstream sequences that were common for the three forms
(Fig. 6). Within these ESTs, 59 sequences of TR1-I preceded 59
sequences of TR1-II. Thus, within the genomic sequences, the
59 exon of TR1-I should be first, the 59 exon of TR1-II, second,
and the 59 exon of TR1-III, third, followed by a fourth exon that
had sequences common for the three TR1 forms.
Interestingly, ESTs that contained 59 sequences for TR1-I
and TR-II had an additional internal stretch of 176 nucleotides,
which was 100% identical to internal sequences of exon 4 of a
mouse apolipoprotein E (ApoE) gene. It should be noted that
known TR1 (chromosome 10) and ApoE (chromosome 7) genes
in mice are located on different chromosomes. If ESTs contain-
ing TR1 and ApoE sequences were formed by alternative splic-
ing, then one possible explanation for their formation is that
mice may have an additional ApoE gene or a pseudogene lo-
cated within the TR1 gene. Alternatively, ESTs containing a
176-nucleotide stretch could be formed by possible novel ge-
netic mechanisms (such as “reverse splicing”), which would
allow insertion of a DNA (or mRNA) sequence within another
DNA (or mRNA) sequence.
Alternative Use of First Exons within TR3 Genes—The ob-
servation of alternative mRNA forms of TR1 in rats and mice
prompted us to test whether this mechanism is used in genes
for other TRs. Indeed, computer search analysis of NR and EST
data bases revealed three alternative human TR3 transcripts
(TR3-I, TR3-II, and TR3-III) that differed in their 59 sequences
(Fig. 7) and were formed by alternative first exon splicing (Fig.
8). TR3-I (accession numbers AF171054, AF044212, AF106697,
and AB019694) was a previously reported nucleus-encoded mi-
tochondrial form of TR3 (5–10). The TR3-II transcript (acces-
sion number AF166127) was a previously identified isoform of
human TR3 mRNA, SelZf2 (26). This transcript appeared to be
inhibitory for TR3 expression since it contained an initiator
ATG codon, followed by an in-frame stop signal, in a different
frame with established TR3 sequences. The TR3-III transcript
(accession number AB019695) encoded a protein that lacked a
mitochondrial signal but instead contained a 5-amino acid ex-
tension. The lack of signal peptides in TR3-III suggested that
the protein could reside in the cytosol.
The human TR3 gene, located on chromosome 22 (accession
number AC000090), was previously sequenced by the Human
Genome Project as evidenced by the BLAST analysis of dbNR.
Organization of the human TR3 gene and its upstream region
are shown in Fig. 8. Comparison of cDNA and genomic se-
quences indicated that alternative TR3-I, TR3-II, and TR3-III
transcripts were formed due to alternative use of three 59 exons
within the gene. We also analyzed partial sequences of the
mouse TR3 gene (accession number AC003066, clone tbx1,
strain 129X1/SvJ ES, from cell line RW4, located on chromo-
some 16) that were generated by the Mouse Genome Project
and partial rat TR3 genomic sequences that were found in the
genomic clone containing an upstream region of the COMT
gene. Analyses of these sequences with an exon finding pro-
FIG. 6. Predicted structural organization of mouse and rat
TR1 genes. Upper portion of the figure shows organization of the TR1
gene in mice and rats. Three alternative forms of TR1 mRNA are
obtained from a single TR1 gene by initiating transcription at exons 1,
2, or 3 (indicated by numbers above exon boxes), followed by alternative
splicing to link a used exon to exon 4. The downstream organization of
the gene is not known (shown as question mark). ATG codons indicate
alternative translation initiation sites. Filled boxes indicate translated
sequences. Open boxes correspond to untranslated regions. Lower por-
tion of the figure shows organization of several ESTs (accession num-
bers AI526517, AI527732, AI226627, AI787452, AI314145, and
AI315024) that were used to determine the order of exons in the TR1
gene. These ESTs contained sequences that were identical with partial
sequences of exon 1, exon 2, and the last exon of the TR1 gene. In
addition, ESTs contained an internal stretch of sequences identical
with internal sequences of exon 4 of apolipoprotein E gene (shown as
ApoE in the upper portion of the figure). FIG. 7. Sequence comparisons of TR3 forms obtained by alter-
native first exon splicing in mice, rats, and humans. A, nucleotide
sequence comparisons of three alternative TR3 cDNA forms. The three
forms utilize alternative first exons (exons 1, 2, or 3), followed by the
common exon (exon 4). Exon-intron splicing sites are shown by inter-
ruptions in horizontal lines. Exonic sequences are shown in uppercase,
and intronic sequences, in lowercase. Numbers on the left and right
indicate nucleotide numbers within GenBankTM genomic sequences
that were used to assemble the figure. Numbers within sequences
indicate numbers of intronic nucleotides present within sequences
shown in the figure. ATG codons that are predicted to initiate transla-
tion of TR3-III mRNAs are shown in bold. These are characterized by
favorable Kozak consensus sequences for phasing mRNA for initiation
of translation. The occurrence of exons 2 and 3 in human sequences is
indicated by the analysis of dbNR. The occurrence of exon 3 in mouse
and rat sequences is predicted in this study based on the analysis of
mouse and rat genomic sequences with an exon-searching program.
Sequences shown are from the following dbNR genomic sequences:
HTR3-I, first form of human TR3 (accession number AC000090),
MTR3-I, first form of mouse TR3 (accession number AC003066),
RTR3-I, first form of rat TR3 (accession number RN5CATOMT), HTR3-
II, second form of human TR3 (accession number AC000090), HTR3-III,
third form of human TR3 (accession number AC000090); MTR3-III,
third form of mouse TR3 (accession number AC003066); RTR3-III, third
form of rat TR3 (accession number RN5CATOMT). B, amino acid se-
quence comparisons of TR3-I and TR3-III. Same sequences were used
here as in Fig. 7A. Exon-intron junctions (indicated by interruptions
within horizontal lines) were predicted with an exon finding program
and by matching cDNA and genomic sequences.
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gram revealed the presence of a predicted conserved exon that
could generate TR3-III forms of mouse and rat TR3 (Fig. 7).
Thus, the use of alternative first exon splicing to form multiple
TR3 forms appeared to be conserved in humans, mice, and rats.
However, no ESTs that corresponded to mouse and rat TR3-III
were detected.
We have previously noted that the human TR3 gene partially
overlapped with the gene for COMT (10). In the present study,
we performed detailed computer analysis of human TR3 and
COMT genes and analyzed whether this structural organiza-
tion of these genes is conserved in other animals. We found that
the first exon of the human TR3 gene overlapped with the first
exon of the gene for membrane-bound (MB)-COMT (Fig. 8). The
mTR3 and MB-COMT genes were located on different DNA
strands on a chromosome 22q11.2 band. Translation of MB-
COMT mRNA resulted in the 30-kDa protein containing an
N-terminal transmembrane domain (27). Interestingly, the
COMT gene, like the human TR3 gene, had an additional
transcription initiation site. The use of this site resulted in a
transcript that lacked the first two exons and translated into a
shorter 26-kDa soluble catechol-O-methyltransferase (S-
COMT) (27). Human DNA sequences containing exon 1 of the
TR3-I gene and exon 1 of the MB-COMT gene were well sepa-
rated from other exons within these genes. For example, tran-
scription start sites for S-COMT and TR3-III were separated by
;30 kilobases (Fig. 8).
Further analysis of mouse and rat TR3 genes revealed that
exons encoding a mitochondrial signal overlapped with the first
exons of mouse and rat MB-COMT genes. Conservation of
structural organization of TR3 and COMT genes in humans,
mice, and rats suggested that certain TR3 and COMT forms
could potentially exhibit parallel or contrasting regulation of
expression.
Alternative Use of First Exons in the Drosophila TR Gene—In
addition to the finding of alternative first exons within mam-
malian TR genes, we detected a Drosophila gene for TR that
produced two alternative transcripts (Fig. 9). Like TR3 forms,
these transcripts encoded proteins that differed in their N-
terminal regions. The previously reported Drosophila TR se-
quence (accession number U81995) corresponded to a putative
cytosolic form of this enzyme, while the additional form of the
protein was evident from the BLAST analysis of dbEST and
was represented by several ESTs (e.g. accession numbers
AA803764 and AA820592 and 6 other ESTs). This second form
of the Drosophila TR contained a predicted mitochondrial sig-
nal peptide. Thus, it is likely that a single Drosophila TR gene
encodes two proteins, mitochondrial and cytosolic. Interest-
ingly, although the order of predicted mitochondrial and cyto-
solic exons was different, the location of the splicing site that
separated variable and common sequences was conserved be-
tween mammalian TR3 and Drosophila TR genes (Fig. 9B).
DISCUSSION
We report in the present study that extensive heterogeneity
exists among animal TRs and that splicing of first exons of TR
genes occurs as a general genetic mechanism for producing
multiple mRNA isoforms. The data suggest that this evolution-
ary conserved genetic mechanism contributes to heterogeneity
that is observed among animal TRs.
The fact that human TR1 isolated from HeLa cells occurs in
at least two distinct forms has been established previously
(16–18). The two forms could be separated by affinity chroma-
tography on a heparin column. The first form was not retained
on a heparin column, exhibited full catalytic activity and sele-
nium content and showed reactivity with anti-rat liver TR1
antibodies. This form could be converted into the high-affinity
TR1 form upon reduction. An additional TR1 form was also
isolated that could bind the heparin column without prior re-
duction. This form contained ;0.5 selenium per subunit and
had reduced catalytic activities and reactivity with anti-rat
liver TR1 antibodies.
Our present study indicates that the number of TR1 forms is
much larger than previously thought and that these forms
differ in electrophoretic mobility on SDS-PAGE and isoelectro-
FIG. 8. Structural organization of human TR3 and COMT
genes. TR3 and COMT genes are located on complementary DNA
stands and overlap in their first exons such that transcription within
the membrane-bound form (MB-COMT) of the COMT gene is initiated
within the coding region of the mitochondrial (TR3-I) form of the TR3
gene. However, transcription start sites in the TR3-III gene and a
soluble form (S-COMT) of the COMT gene are separated by ;30 kilo-
bases. Alternative first exon splicing is used in the TR3 gene. TR3-I
mRNA is composed of 6 exons (exons 1 and 4–8); TR3-II mRNA, 6 exons
(exons 2 and 4–8); TR3-III mRNA, 6 exons (3–8); MB-COMT mRNA, 6
exons (exons 1–6); and S-COMT mRNA, 4 exons (exons 3–6). Transla-
tion start sites within TR3 and COMT genes are indicated by ATG
codons. Initiator ATG codon for TR3-I mRNA is located within exon 1,
and for TR3-III mRNA, within exon 2. Translation start site for TR3-II
is located within exon 2, but followed by an in-frame stop signal (not
shown). The translation initiation site in the MB-COMT mRNA is the
first ATG within exon 3, and in the S-COMT mRNA, the second ATG
within exon 3. Filled boxes indicate translated sequences. Open boxes
correspond to untranslated regions. FIG. 9. Alternative forms of Drosophila TR. A, structural organi-
zation of the Drosophila TR gene. Each numbered box represents an
exon within the gene. Open boxes show untranslated regions, and filled
boxes, coding regions. There are two alternative forms of Drosophila TR
mRNA that are encoded by either exons 1 and 3–5 (DTR-I, accession
number U81995), or exons 2–5 (DTR-II; accession number AA803764
and AA820592). B, amino acid sequences of N-terminal regions of two
alternative Drosophila TR sequences. Human TR3-I and TR3-III, which
deviate from each other at the same site within the intron-exon struc-
ture, are shown for comparison. Boxed residues represent predicted
mitochondrial signal peptides. The vertical line represents exon-intron
junctions. Identical residues within four sequences are highlighted. The
horizontal line over the sequences shows the location of the disulfide
active center.
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focusing gels. In particular, minor 67-kDa isoforms of TR1 were
detected in our study that migrated significantly slower on
SDS-PAGE gels than would be predicted from previously re-
ported gene sequences. To characterize various mouse TR1
forms, we used affinity chromatography on ADP-Sepharose.
Interestingly, this simple technique was sufficient to enrich
TR1 to an extent that it could be directly analyzed on two-
dimensional gels and visualized by protein staining. Since mul-
tiple forms of TR1 were visualized after only a single isolation
step, this procedure may provide a basis for future high-
throughput protein microchemistry analyses of TRs isolated
from multiple sources or under various conditions.
To define the basis for heterogeneity within human and
mouse enzyme preparations, we initially used protein micro-
chemistry techniques and established that detected tryptic
peptides did not differ between various enzyme isoforms that
had different electrophoretic mobility on polyacrylamide gels or
were isolated from normal or malignant cells. It remains to be
determined what post-translational modifications, if any, are
involved in the formation of 55–57-kDa TR1 forms in humans
and mice.
To further characterize a mechanism responsible for the
formation of multiple TR1 forms and, in particular, for the
occurrence of 67-kDa TR1 species, we turned our attention to
possible genetic mechanisms. Since no mouse TR1 sequences
were available in sequence data bases, we initially determined
the mouse TR1 cDNA sequence. Interestingly, this cDNA en-
coded a protein of 67 kDa that was formed from a coding region
starting with an ATG codon (in a favorable Kozak consensus
sequence for phasing the message for translation) upstream of
the previously predicted translation start site. The predicted
extended N-terminal domain had no homology to known pro-
tein sequences, and at present its function is not known.
Recently, several new mammalian TR1 cDNA sequences,
including one for mouse TR1 (28), were deposited into Gen-
BankTM. Examination of NR and EST sequences and their
comparison to the mouse TR1 cDNA sequence that was deter-
mined in the present study, revealed three forms of mouse and
rat TR1 cDNAs that had unrelated 59 sequences, but common
downstream sequences. We also observed three human TR1
forms (BE618239, AU077310, and previously known TR1 se-
quences) obtained by alternative exon splicing. The location of
an alternative splicing site was conserved among mouse, rat,
and human TR1 genes.
Alternative first exon splicing that was found to be used to
synthesize alternative mRNA forms of mouse and rat TR1
mRNA is a previously recognized genetic phenomenon (29). It
is used to accommodate requirements for elevated expression of
a protein in a tissue-specific manner and to synthesize protein
species that differ in their intracellular location (e.g. alterna-
tive forms may contain or lack an organelle-targeting signal
peptide or a trans-membrane domain). In addition, alternative
first exon splicing may be used as an on/off switch, which
functions by alternative expression of protein-expressing and
protein-suppressing mRNA forms. In this case, the “off” form
would contain additional upstream initiation sites followed by
stop signals that would suppress protein expression, whereas
the “on” form would produce a functional protein.
Well characterized examples of alternative first exon splicing
include genes of enzymes that are involved in “liver-associated”
xenobiotic metabolism and detoxification. The human microso-
mal glutathione S-transferase utilizes four alternative first
exons, two of which appear to be functional and result in mRNA
sequences differing in the 59-untranslated region, and two non-
functional forms as they contain additional upstream out of
frame initiation signals (30). These four mRNA forms were
predicted to be generated from a common promoter. The rat
g-glutamyltransferase gene also has four alternative first ex-
ons but utilizes four alternative promoters to form mRNA
species differing in the 59-untranslated region but encoding
identical proteins (31). Additional examples of alternative first
exon splicing include family 19 of the cytochrome P450 gene
superfamily (32) and the UDP-glucoronosyltransferase gene
(33), which contain numerous first exons but a common splice
junction located upstream of the translation start site.
One interesting observation made in the present study is
that several mouse ESTs contained apolipoprotein E sequences
within the TR1 sequences. Since all these ESTs originate from
the same cDNA library (Sugano mouse kidney mkia), addi-
tional sequences from other sources may be required to confirm
the observed puzzling location of the ApoE sequences. If con-
firmed, the finding that an ApoE gene is located within the
mouse TR1 gene may have important biomedical implications.
Previous molecular genetic studies identified three genes (pre-
senilin 1, presenilin 2, and b-amyloid precursor protein) asso-
ciated with early onset of Alzheimer’s disease (AD), and one
gene (ApoE) associated with late onset of AD (34). An addi-
tional AD susceptibility locus has been mapped to a broad
region of chromosome 12, but the gene responsible for a defect
has not been identified. Whereas the human ApoE gene resides
on chromosome 19, the TR1 gene is located on human chromo-
some 12. If a mouse TR1 gene indeed contains an additional
ApoE gene and this gene organization is conserved in humans,
then a new ApoE gene may provide an additional susceptibility
marker for AD. Alternatively, the ApoE sequences located
within the mouse TR1 gene may be a part of an ApoE pseudo-
gene, or the internal ApoE sequences could have been incorpo-
rated into TR1 sequences by an unknown genetic mechanism.
To confirm the predicted organization of mouse and rat TR1
genes and to determine the actual mechanism involved in
linking TR1 and ApoE sequences, we have to wait until actual
sequences of TR1 genes are available.
Having determined the use of alternative first exon splicing
in regulation of expression of mouse and rat TR1 mRNAs, we
tested whether this mechanism is used to express multiple
forms of other TRs. Indeed, two unrelated 59-end sequences,
followed by common downstream sequences were evident from
the analysis of two human TR2 cDNA sequences (EST se-
quence, accession number AA460989, and a cDNA sequence,
accession number AF133519). However, the lack of full-size
cDNAs and genomic sequences for mammalian TR2 did not
allow us to evaluate the significance of this finding.
The analysis of mammalian TR3 genes was more fruitful and
revealed a remarkable genetic complexity within genomic seg-
ments that contained TR3 genes. Like mouse and rat TR1
genes, the human TR3 gene contained three alternative first
exons. However, the previously defined translation initiation
site was located upstream of the first common exon and thus
the use of alternative first exons resulted in different N-termi-
nal sequences of the protein. The use of exon 1 resulted in the
formation of a mitochondrial form of the enzyme, TR1-I (exon 1
encoded a mitochondrial signal peptide). The use of exon 2
instead of exon 1 generated an mRNA form (TR3-II) that con-
tained an upstream out of frame initiation site followed by a
termination signal. This form could potentially be used as an
off switch. If exon 3 was used in place of either exon 1 or exon
2, the N-terminal sequence of TR3 was extended by only 5
residues. The lack of signal sequences within TR3-III sug-
gested that this protein could be located in the cytosol.
Such a complex organization of TR3 genes was even more
complicated by the fact that exon 1 of human, mouse, and rat
TR3 genes overlapped with exon 1 of the MB-COMT gene
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located on a complementary DNA strand. It has previously
been established that the COMT gene gives rise to two alter-
native protein forms, a membrane-bound and a soluble form
(27). Only the MB-COMT mRNA had common sequences with
TR3 mRNA, and only TR3-I mRNA (mitochondrial form) over-
lapped with MB-COMT mRNA. Interestingly, the COMT
knockout mice have been previously generated and found to
exhibit sexually dimorphic changes in catecholamine levels and
behavior (35). No sufficient experimental details were reported
(35) to evaluate whether knockouts could have affected expres-
sion of some of the TR3 forms. It is also not known whether TR3
could be involved in psychiatric disorders and symptoms, in-
cluding the psychopathology associated with the 22q11 mi-
crodeletion, the area of the human chromosome 22, where the
COMT and TR3 genes are located.
Availability of the completely sequenced Drosophila genome
and a large number of EST sequences allowed us to test if
alternative first exon splicing is also used in Drosophila. We
identified two alternative exons within the Drosophila TR gene
that generated predicted mitochondrial and cytosolic enzymes.
Interestingly, the site for junction of alternative first exons and
a common downstream exon was conserved between mamma-
lian TR3 and Drosophila TR genes, suggesting a close evolu-
tionary relation between these genes. In addition, homology
and phylogenetic analyses (data not shown) indicated slightly
higher evolutionary linkage between Drosophila TR and mam-
malian TR3 genes than between mammalian TR1 and TR3
genes.
In conclusion, we identified alternative exon splicing as a
general mechanism to express multiple mRNA forms of animal
TRs. Such mRNA forms encoded proteins that have common or
different N-terminal sequences and that were responsible, at
least in part, for observed heterogeneity within animal TR
preparations. The use of alternative first exon splicing has not
been described previously for any known selenoprotein. Fur-
ther studies are required to determine the functional role of
alternative first exon splicing in regulation of expression and
function of animal thioredoxin reductases.
Addendum—A recent paper by Rundlof et al. (36) also reported
identification of three variants of rodent TR1 mRNA.
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